Curated News
By: NewsRamp Editorial Staff
November 17, 2026

NanoViricides Advances NV-387 into Phase 2 Trials for Ebola and Mpox

TLDR

  • NanoViricides advances NV-387 into two Phase 2 trials for Ebola and mpox, plus FDA designations for measles, positioning NNVC ahead in broad-spectrum antiviral development.
  • NanoViricides filed its 10-Q showing NV-387 Oral Gummies began Phase 2 enrollment for Ebola Bundibugyo and mpox, with FDA Orphan Drug and Rare Pediatric Disease designations for measles.
  • NanoViricides' NV-387 trials for Ebola and mpox could bring broad-spectrum antiviral treatment to underserved regions and improve global outbreak preparedness.
  • NanoViricides' NV-387 is a broad-spectrum antiviral nanoviricide being tested against Ebola, mpox and measles, with Ebola trial enrollment starting September 23 in the DRC.

Impact - Why it Matters

This news matters because it marks a critical step forward in developing a broad-spectrum antiviral that could address multiple high-consequence infectious diseases. The initiation of Phase 2 trials for Ebola and mpox demonstrates tangible progress in clinical development, potentially bringing new treatment options to areas with limited therapeutic choices. The FDA designations for measles further underscore the drug's potential to address rare pediatric diseases. For investors, these advancements signal momentum in NanoViricides' pipeline and may attract nondilutive funding, while for public health, a successful broad-spectrum antiviral could enhance preparedness against outbreaks and provide versatile tools against emerging viral threats.

Summary

NanoViricides, Inc. (NYSE American: NNVC) has filed its quarterly report on Form 10-Q for the fiscal quarter ended Sept. 30, 2026, spotlighting significant progress for its broad-spectrum antiviral candidate NV-387 Oral Gummies. The company has advanced NV-387 into two Phase 2 clinical trials: enrollment began Sept. 23 for a trial evaluating the drug against Ebola Bundibugyo virus disease in the Democratic Republic of the Congo, while a separate Phase 2 trial site opened the same day to test the treatment for mpox. NanoViricides independently funded the Ebola trial and established clinical testing infrastructure, including on-site molecular diagnostic capabilities, to support its research efforts.

The company also highlighted U.S. Food and Drug Administration (FDA) Orphan Drug and Rare Pediatric Disease designations granted to NV-387 for measles treatment in April and May 2026, respectively. NanoViricides plans to pursue a Phase 2 measles trial and seek nondilutive funding, including potential U.S. government grants, to advance development. NV-387 remains investigational, with its effectiveness for these indications under clinical evaluation. For full details, see the press release.

NanoViricides, Inc. (www.nanoviricides.com) is a clinical-stage company creating special purpose nanomaterials for antiviral therapy. Its novel nanoviricide™ class of drug candidates and technology are based on intellectual property from TheraCour Pharma, Inc., with a Memorandum of Understanding for antiviral drug development. The company holds broad exclusive licenses for several virus fields and focuses on advancing NV-387 for RSV, COVID, Long COVID, Influenza, MPOX/Smallpox, and Measles, as well as NV-HHV-1 for Shingles. InvestorWire, a specialized communications platform, powered by IBN, distributed the announcement.

Source Statement

This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, NanoViricides Advances NV-387 into Phase 2 Trials for Ebola and Mpox

Blockchain registration record for this content